Literature DB >> 26497825

Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.

Noam A VanderWalde1,2, Michelle T Chi3, Arti Hurria4, Matthew D Galsky5, Matthew E Nielsen6.   

Abstract

PURPOSE: Despite the fact that bladder cancer patients have the highest median age of any type of cancer, older patients with muscle invasion are often under-treated.
METHODS: In this review, we report the most up to date literature on the patterns of care and treatment of older patients with muscle invasive bladder cancer. Data on under-treatment, geriatric principles, cystectomy, perioperative chemotherapy, and bladder preservation for older patients are presented and analyzed.
CONCLUSION: Chronologic age should not exclude patients from curative-intent therapy. Functional age as determined by geriatric assessments and multidisciplinary evaluation can help clinicians decide on the best course of treatment for individual patients. Cystectomy, perioperative chemotherapy, and curative-intent bladder preservation are reasonable options in healthy older adults. Observation should be limited to patients with extremely poor performance status and very limited life expectancy.

Entities:  

Keywords:  Antineoplastic agents; Cystectomy; Geriatric assessment; Radiotherapy; Urinary bladder neoplasms

Mesh:

Substances:

Year:  2015        PMID: 26497825     DOI: 10.1007/s00345-015-1708-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  56 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Radical cystectomy in patients over 80 years old in Quebec: A population-based study of outcomes.

Authors:  Ahmed S Zakaria; Fabiano Santos; Simon Tanguay; Wassim Kassouf; Armen G Aprikian
Journal:  J Surg Oncol       Date:  2015-02-08       Impact factor: 3.454

3.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

4.  Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).

Authors:  Jean-Léon Lagrange; Caroline Bascoul-Mollevi; Lionnel Geoffrois; Véronique Beckendorf; Jean-Marc Ferrero; Florence Joly; Nedjila Allouache; Jean-Marc Bachaud; Christine Chevreau; Andrew Kramar; Bruno Chauvet
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-10       Impact factor: 7.038

5.  Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

Authors:  Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

6.  The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

Authors:  D S Kaufman; K A Winter; W U Shipley; N M Heney; M P Chetner; L Souhami; R A Zlotecki; W T Sause; L D True
Journal:  Oncologist       Date:  2000

7.  Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.

Authors:  M H Hussain; T R Glass; J Forman; W Sakr; D C Smith; M Al-Sarraf; J Jones; S P Balcerzak; E D Crawford; H B Grossman
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

Review 8.  Geriatric assessment in surgical oncology: a systematic review.

Authors:  Megan A Feng; Daniel T McMillan; Karen Crowell; Hyman Muss; Matthew E Nielsen; Angela B Smith
Journal:  J Surg Res       Date:  2014-07-05       Impact factor: 2.192

9.  Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.

Authors:  Daniel Herchenhorn; Rodrigo Dienstmann; Fabio A Peixoto; Franz S de Campos; Valdelice O Santos; Denise M Moreira; Hedilene Cardoso; Isabele A Small; Carlos G Ferreira
Journal:  Int Braz J Urol       Date:  2007 Sep-Oct       Impact factor: 1.541

10.  Benefit of radical cystectomy in the elderly patient with significant co-morbidities.

Authors:  Scott B Farnham; Michael S Cookson; Gregory Alberts; Joseph A Smith; Sam S Chang
Journal:  Urol Oncol       Date:  2004 May-Jun       Impact factor: 3.498

View more
  6 in total

1.  Evolving concepts in muscle-invasive bladder cancer.

Authors:  Peter C Black; Wassim Kassouf
Journal:  World J Urol       Date:  2016-01       Impact factor: 4.226

2.  Robotic radical cystectomy and enhanced recovery: a new pathway.

Authors:  S S Goonewardene; R Persad; D Gillatt
Journal:  World J Urol       Date:  2016-03-24       Impact factor: 4.226

Review 3.  Challenge of cancer in the elderly.

Authors:  Christine Marosi; Marcus Köller
Journal:  ESMO Open       Date:  2016-04-12

Review 4.  Advances in surgical management of muscle invasive bladder cancer.

Authors:  Janet Baack Kukreja; Jay B Shah
Journal:  Indian J Urol       Date:  2017 Apr-Jun

5.  Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).

Authors:  Hiromichi Iwamura; Shingo Hatakeyama; Masaki Momota; Yuta Kojima; Takuma Narita; Teppei Okamoto; Naoki Fujita; Itsuto Hamano; Kyou Togashi; Tomoko Hamaya; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Transl Androl Urol       Date:  2021-03

6.  The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.

Authors:  Kai Ozaki; Shingo Hatakeyama; Toshikazu Tanaka; Daisuke Noro; Noriko Tokui; Hirotaka Horiguchi; Yoshiharu Okuyama; Naoki Fujita; Teppei Okamoto; Akiko Okamoto; Yuichiro Suzuki; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  BJUI Compass       Date:  2021-10-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.